MCM10 promotes hepatocellular carcinoma progression through cyclin D1 regulation

Table 1 Correlation of MCM10 protein expression with clinicopathological parameters, n (%)

Characteristics	All case	MCM10 expression		P value
		Low	High
Cases	147	85	62
Age (years)				0.985
≤ 50	76 (51.7)	44 (51.8)	32 (51.6)
> 50	71 (48.3)	41 (48.2)	30 (48.4)
Gender				0.763
Male	129 (87.8)	74 (87.1)	55 (88.7)
Female	18 (12.2)	11 (12.9)	7 (11.3)
HBsAg				0.787
Negative	30 (20.4)	18 (21.2)	12 (19.4)
Positive	117 (79.6)	67 (78.8)	50 (80.6)
ALT (U/L)				0.779
≤ 40	81 (55.1)	46 (54.1)	35 (56.5)
> 40	66 (44.9)	39 (45.9)	27 (43.5)
TBil (μmol/L)				0.165
≤ 17.1	110 (74.8)	60 (70.6)	50 (80.6)
> 17.1	37 (25.2)	25 (29.4)	12 (19.4)
PT (s)				0.348
≤ 13.5	131 (89.1)	74 (87.1)	57 (91.9)
> 13.5	16 (10.9)	11 (12.9)	5 (8.1)
ALB (g/L)				0.885
≥ 35	137 (93.2)	79 (92.9)	58 (93.5)
< 35	10 (6.8)	6 (7.1)	4 (6.5)
AFP (ng/mL)				0.031
≤ 200	93 (63.3)	60 (70.6)	33 (53.2)
> 200	54 (36.7)	25 (29.4)	29 (46.8)
Capsule integrity				0.050
Complete	66 (44.9)	44 (51.8)	22 (35.5)
No/incomplete	81 (55.1)	41 (48.2)	40 (64.5)
Tumor number				0.635
Single	105 (71.4)	62 (72.9)	43 (69.4)
Multiple (≥ 2)	42 (28.6)	23 (27.1)	19 (30.6)
Tumor differentiation				0.889
I-II	82 (55.8)	47 (55.3)	35 (56.5)
III-IV	65 (44.2)	38 (44.7)	27 (43.5)
Tumor size				0.721
≤ 5 cm	57 (38.8)	34 (40.0)	23 (37.1)
> 5 cm	90 (61.2)	51 (60.0)	39 (62.9)
T stage				0.034
T1-T2	106 (72.1)	67 (78.8)	39 (62.9)
T3-T4	41 (27.9)	18 (21.2)	23 (37.1)
Vascular invasion				0.080
No	106 (72.1)	66 (71.8)	40 (72.6)
Yes	41 (27.9)	19 (28.2)	22 (27.4)
BCLC stage				0.280
A-B	102 (69.4)	56 (65.9)	46 (74.2)
C	45 (30.6)	29 (34.1)	16 (25.8)

Bold values indicate significant P < 0.05. ALT: Alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; TBil: Total bilirubin; PT: Prothrombin time; ALB: Albumin; AFP: Alpha-fetoprotein; HBsAg: Hepatitis B surface antigen.